Medaphor Group PLC ScanTrainer at Central Middlesex Hospital

TIDMMED

Medaphor Group PLC

07 June 2018

7 June 2018

MedaPhor Group plc

("MedaPhor" or the "Group" or the "Company")

ScanTrainer installed at Central Middlesex Hospital

MedaPhor Group plc (AIM: MED), the intelligent ultrasound software and simulation company, announces that ScanTrainer, the OBGYN and General Medical simulator training platform, has been installed at a new Ultrasound Training Academy at Central Middlesex Hospital, London, UK.

The London North West Healthcare NHS Trust (LNWH) has chosen ScanTrainer for its new state-of-the-art ultrasound education facility based at Central Middlesex Hospital. The Academy has been designed to ease growing ultrasound training pressures and clinical demands across the Trust and beyond.

Following an assessment of the ultrasound simulation market, the Trust purchased a ScanTrainer Transvaginal Simulator (TVS) and a ScanTrainer Transabdominal Simulator (TAS) to support the Trust in making training more accessible for those learning and improving their ultrasound skills.

Tanuja Khiroya, Clinical Lead Radiology & Medical Physics, at Central Middlesex Hospital, who pioneered and led the project, commented: "Historically ultrasound trainees would have completed the bulk of their learning in the clinic or by using text books. ScanTrainer represents a step-change by enabling clinicians to learn independently in a patient-safe environment before practising on patients. This ensures that trainees are not only acquiring skills faster but are well equipped and confident when it comes to scanning real patients for the first time."

Ian Whittaker, Chief Operating Officer, at MedaPhor, said: "We have seen the emergence of a number of ultrasound academies across the UK recently with Norwich, Leeds, Peninsula, Wales and, of course, Central Middlesex being some of the pioneers in this space. It's very encouraging to see ultrasound skills initiatives such as these taking strides to close the skills gap and MedaPhor is delighted to be able to equip them with simulation technologies that can help them achieve their goals."

 
MedaPhor Group plc                                            www.medaphor.com 
Stuart Gall, CEO                                      Tel: [phone] 
 Ian Whittaker, COO 
 
Cenkos Securities                                     Tel: [phone] 
Camilla Hume (Nominated Advisor) 
Michael Johnson / Julian Morse (Corporate 
 Broking) 
 
Walbrook PR                Tel: [phone] or [e-mail] 
Paul McManus / Anna            Mob: [phone] / Mob: [phone] 
 Dunphy                                                                    001 
 
 

About MedaPhor (www.investors.medaphor.com)

MedaPhor (AIM: MED), the intelligent ultrasound software and simulation company, develops artificial intelligence-based clinical image analysis software tools, augmented reality-based needle guidance software and advanced hi-fidelity haptic and manikin-based training simulators for medical practitioners.

Based in Cardiff and Oxford in the UK, Atlanta in the US and Hong Kong in Asia, MedaPhor operates two divisions:

Intelligent Ultrasound Simulation Division

Focuses on hi-fidelity ultrasound education and training through simulation. Its three main products are the ScanTrainer OBGYN and General Medical simulator training platform, the HeartWorks echocardiography simulator platform and the BodyWorks Eve Point of Care and Emergency Medicine Simulator. Over 500 MedaPhor simulators have been sold to over 300 medical institutions in over 30 countries around the world.

Intelligent Ultrasound Clinical Division

Focuses on augmented reality and deep-learning based algorithms to make ultrasound machines smarter and more accessible. Products in development include ScanNav and NeedleGuide. ScanNav uses machine-learning based algorithms to automatically identify, grade and capture good ultrasound images. NeedleGuide aims to simplify ultrasound-guided needling by using deep learning and augmented reality to provide the user with pathway guidance and automated tracking for a range of medical procedures.

Some products in the pipeline may require US FDA approval, as such this material should be considered informational only and does not constitute an offer to sell or infer claims or benefits.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

NRAEASKKEDSPEFF

(END) Dow Jones Newswires

June 07, 2018 02:01 ET (06:01 GMT)